You are here

Our History

CRT has 30 years’ specialist experience in the commercialisation of cancer research and a proven track record of successful innovation.

2002: Cancer Research Technology (CRT) is formed Open

CRT is formed by combining the strengths and employees of its predecessor technology transfer companies, Cancer Research Campaign Technology (CRCT), Cancer Research Ventures (CRV) and Imperial Cancer Research Technology (ICRT).

2005: CRT Discovery Laboratories (CRT-DL) scale-up operations Open

CRT Discovery Laboratories (CRT-DL) move from Dominion House, St. Bartholomew’s Hospital to The Wolfson Institute of Biomedical Research at UCL. The move facilitates a scale-up of operations later in the year as the number of projects bought into the laboratories increase.

Read more about CRT-DL

2006: CRT Inc. and Clinical Development Partnerships (CDP) established Open

CRT Inc. is established as our US subsidiary, based in Boston. Dr Larry Steranka is appointed as Managing Director. The Clinical Development Partnerships (CDP) is launched by CRT and Cancer Research UK to bring new life to promising therapies that have been de-prioritised by pharma and biotech companies.

Read more about CRT Inc.
Read more about CDP

2008: Cancer Therapeutics CRC Pty Ltd (CTx) commences operations Open

Cancer Therapeutics CRC (CTx) – our discovery alliance in Australia – commences operations as one of the largest public/private partnerships of its type in the world. A dedicated cancer drug discovery and development company, CTx works closely with leading Australian researchers and institutes to identify, protect and develop small molecule discoveries.

Visit the CTx website

2009: Sales of Temozolomide reach $1 billion Open

Sales of Temozolomide (Temodal®), an anti-cancer drug developed by Cancer Research UK scientists and licensed to Schering-Plough through CRT, reach $1 billion. It is the first line treatment for the most common type of adult brain tumour.

Learn more about Temozolomide on the CRUK Science Blog

2010: CRT enters major industry alliance with AstraZeneca Open

CRT enters into a major multi-project alliance with AstraZeneca to create ‘cancer metabolism’ drugs. This is quickly followed by the announcement of a partnership with Cephalon to collaborate on the development of small molecule inhibitors.

Read the press release

2012: CRT and The EIF unveil innovative £50M cancer fund Open

CRT and the European Investment Fund (EIF) join together to create a £50M investment fund to bridge the funding gap in the UK between cancer drug discovery and early development. The CRT Pioneer Fund takes potential cancer drugs from discovery through to entry to Phase II clinical trials. It is a bold step to fund the most innovative oncology research and to plug a large gap in the UK funding of drug discovery.

 

Learn more about the CRT Pioneer Fund
Read the press release

2012: CRT completes two major deals with Astex Pharmaceuticals Open

CRT, Astex Pharmaceuticals and The Institute of Cancer Research initiate a collaboration to discover and develop drug candidates targeting an undisclosed epigenetic target. The following month, CRT signs a major five-year strategic drug discovery alliance with Astex and Newcastle University to discover and develop new cancer drugs in collaboration with researchers at the Northern Institute for Cancer Research (NICR).

 

Read the ICR press release
Read the Newcastle University press release

2013: FORMA Therapeutics and CRT announce bold research initiative Open

FORMA Therapeutics and CRT announce a bold research initiative to discover innovative tools, technologies and therapeutic drug candidates against a variety of protein homeostasis regulators called, deubiquitinating enzymes (DUBs).

Read the press release

2013: CRT and Teva Pharmaceuticals form R&D alliance for DDR drugs Open

Building on a prior well-established working relationship, CRT and Teva Pharmaceuticals sign a multi-project alliance agreement to research and develop first-in-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells.

Read the press release

  • CRT is formed by combining the strengths and employees of its predecessor technology transfer companies, Cancer Research Campaign Technology (CRCT), Cancer Research Ventures (CRV) and Imperial Cancer Research Technology (ICRT).

  • CRT Discovery Laboratories (CRT-DL) move from Dominion House, St. Bartholomew’s Hospital to The Wolfson Institute of Biomedical Research at UCL. The move facilitates a scale-up of operations later in the year as the number of projects bought into the laboratories increase.

    Read more about CRT-DL

  • CRT Inc. is established as our US subsidiary, based in Boston. Dr Larry Steranka is appointed as Managing Director. The Clinical Development Partnerships (CDP) is launched by CRT and Cancer Research UK to bring new life to promising therapies that have been de-prioritised by pharma and biotech companies.

    Read more about CRT Inc.
    Read more about CDP

  • Cancer Therapeutics CRC (CTx) – our discovery alliance in Australia – commences operations as one of the largest public/private partnerships of its type in the world. A dedicated cancer drug discovery and development company, CTx works closely with leading Australian researchers and institutes to identify, protect and develop small molecule discoveries.

    Visit the CTx website

  • Sales of Temozolomide (Temodal®), an anti-cancer drug developed by Cancer Research UK scientists and licensed to Schering-Plough through CRT, reach $1 billion. It is the first line treatment for the most common type of adult brain tumour.

    Learn more about Temozolomide on the CRUK Science Blog

  • CRT enters into a major multi-project alliance with AstraZeneca to create ‘cancer metabolism’ drugs. This is quickly followed by the announcement of a partnership with Cephalon to collaborate on the development of small molecule inhibitors.

    Read the press release

  • CRT and the European Investment Fund (EIF) join together to create a £50M investment fund to bridge the funding gap in the UK between cancer drug discovery and early development. The CRT Pioneer Fund takes potential cancer drugs from discovery through to entry to Phase II clinical trials. It is a bold step to fund the most innovative oncology research and to plug a large gap in the UK funding of drug discovery.

     

    Learn more about the CRT Pioneer Fund
    Read the press release

  • CRT, Astex Pharmaceuticals and The Institute of Cancer Research initiate a collaboration to discover and develop drug candidates targeting an undisclosed epigenetic target. The following month, CRT signs a major five-year strategic drug discovery alliance with Astex and Newcastle University to discover and develop new cancer drugs in collaboration with researchers at the Northern Institute for Cancer Research (NICR).

     

    Read the ICR press release
    Read the Newcastle University press release

  • FORMA Therapeutics and CRT announce a bold research initiative to discover innovative tools, technologies and therapeutic drug candidates against a variety of protein homeostasis regulators called, deubiquitinating enzymes (DUBs).

    Read the press release

  • Building on a prior well-established working relationship, CRT and Teva Pharmaceuticals sign a multi-project alliance agreement to research and develop first-in-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells.

    Read the press release